This article was originally published in The Gray Sheet
Executive SummaryNets $9.4 mil. in an offering of 2.35 mil. common shares. The Sunnyvale, California-based blood analysis systems manufacturer registered the shares with the Securities and Exchange Commission in August ("The Gray Sheet" Sept. 5, p. 23). The proceeds, according to the company, will help "enable Abaxis to measurably improve its liquidity and focus the necessary resources on" commercializing the VetScan veterinary product and on gaining FDA marketing clearance for the Piccolo point of care whole blood analyzer system and bringing the product to market
You may also be interested in...
The Chinese government's plan to reduce tariffs it imposed on a slew of US exports is expected to have minimal impact on the overall medtech industry. See what Ralph Ives, AdvaMed's executive VP for global strategy, said about it here.
FDA approved sNDAs from GlaxoSmithKline for diclofenac-containing Voltaren Arthritis Pain for the temporary relief of arthritis pain and from Alcon for Pataday olopatadine drops at 0.2% concentration for once-daily use temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair or dander and 0.1% for twice-daily use for the same indications plus redness relief.